title: Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.
authors.affiliation: a Emeritus; Vaccinogen, Inc. ; Frederick , MD USA.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Hanna
authors.forename: Jason
authors.initials: J
authors.lastname: Howard
authors.forename: Jan
authors.initials: J
authors.lastname: Vermorken
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D014644:Genetic Variation / Q000235:genetics / Q000276:immunology; D006801:Humans; D016233:Immunotherapy, Active; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy
chemical_list: D000276:Adjuvants, Immunologic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines
keywords: Bacillus Calmette Guerin (BCG); T-cell responses; active specific immunotherapy; colon tumor; delayed-typed hypersensitivity; human monoclonal antibodies; tumor heterogeneity; tumor immunity; tumor-associated antigens